Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts.
K22 strain
PPV
PPV-27a
efficacy
Journal
Veterinary medicine (Auckland, N.Z.)
ISSN: 2230-2034
Titre abrégé: Vet Med (Auckl)
Pays: New Zealand
ID NLM: 101724251
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
11
2019
accepted:
20
01
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2020
Statut:
epublish
Résumé
Porcine parvovirus (PPV), the causative agent of severe reproductive failures in pigs, is present worldwide. The witnessed spread of the virulent 27a type PPV strains since its recognition raised concerns about the efficacy of the available commercial vaccines. To address this question, vaccinated pregnant gilts were challenged with a PPV-27a-like virus strain and parameters related to vaccine efficacy were compared. The K22 vaccine strain of Parvoruvax Stronger protection was provided by the "Kresse-like" K22 PPV strain-based vaccine than by the NADL-2 and NADL-like strain-based commercial vaccines against a PPV-27a cluster strain challenge. Vaccine-induced antibody levels as measured pre-challenge were not found to be an accurate indicator of protection.
Sections du résumé
BACKGROUND/INTRODUCTION
BACKGROUND
Porcine parvovirus (PPV), the causative agent of severe reproductive failures in pigs, is present worldwide. The witnessed spread of the virulent 27a type PPV strains since its recognition raised concerns about the efficacy of the available commercial vaccines.
METHODS
METHODS
To address this question, vaccinated pregnant gilts were challenged with a PPV-27a-like virus strain and parameters related to vaccine efficacy were compared.
RESULTS
RESULTS
The K22 vaccine strain of Parvoruvax
CONCLUSION
CONCLUSIONS
Stronger protection was provided by the "Kresse-like" K22 PPV strain-based vaccine than by the NADL-2 and NADL-like strain-based commercial vaccines against a PPV-27a cluster strain challenge. Vaccine-induced antibody levels as measured pre-challenge were not found to be an accurate indicator of protection.
Identifiants
pubmed: 32158645
doi: 10.2147/VMRR.S236912
pii: 236912
pmc: PMC7048948
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17-24Informations de copyright
© 2020 Kiss et al.
Déclaration de conflit d'intérêts
Dr Pál Bajnóczi is employed by Prophyl Kft. (Ltd.) and receives personal fees (salary) from Prophyl Kft as an employee. Prophyl Kft. is subcontracted by CEVA Santé Animale S. A. to perform animal studies, and Prophyl Kft. received service fee from CEVA Santé Animale S.A. for the conduct of the study. I. Kiss, E. Kovács, A. Cságola, P. Mortensen, & V. Palya are employed by Ceva. The authors report no other conflicts of interest in this work.
Références
J Gen Virol. 2011 Nov;92(Pt 11):2628-2636
pubmed: 21795474
J Gen Virol. 2016 Jun;97(6):1408-1413
pubmed: 26939976
Nucleic Acids Res. 2009 Jan;37(Database issue):D436-42
pubmed: 18981051
Infect Genet Evol. 2015 Dec;36:300-306
pubmed: 26453771
J Gen Virol. 2009 Oct;90(Pt 10):2437-2441
pubmed: 19535504
J Virol. 2001 Mar;75(6):2729-40
pubmed: 11222696
Transbound Emerg Dis. 2017 Dec;64(6):1945-1952
pubmed: 27882679
Res Vet Sci. 2018 Oct;120:28-32
pubmed: 30170185
Am J Vet Res. 1984 Nov;45(11):2403-7
pubmed: 6098200
J Gen Virol. 2006 Feb;87(Pt 2):295-301
pubmed: 16432014
Infect Genet Evol. 2012 Aug;12(6):1163-71
pubmed: 22575819
BMC Bioinformatics. 2007 Aug 29;8:316
pubmed: 17727718
BMC Genomics. 2008 Jan 07;9:5
pubmed: 18179705
Viral Immunol. 2002;15(2):373-84
pubmed: 12081019
Infect Genet Evol. 2017 Mar;48:19-26
pubmed: 27932285
Aust Vet J. 1976 Feb;52(2):80-4
pubmed: 985234
J Virol Methods. 2015 Jun 15;218:46-50
pubmed: 25779824
Virol J. 2019 Jun 3;16(1):75
pubmed: 31159841
J Virol Methods. 1999 Mar;78(1-2):191-8
pubmed: 10204709
J Gen Virol. 2013 Sep;94(Pt 9):2050-2055
pubmed: 23804570
Vet Immunol Immunopathol. 2017 Sep;191:51-59
pubmed: 28895867
J Vet Med B Infect Dis Vet Public Health. 2005 Sep-Oct;52(7-8):323-6
pubmed: 16316393
Nat Rev Genet. 2008 Apr;9(4):267-76
pubmed: 18319742
Arch Virol. 2012 Jun;157(6):1003-10
pubmed: 22383055
Vet Microbiol. 1991 Jun;28(1):1-11
pubmed: 1653481
J Gen Virol. 2007 Feb;88(Pt 2):420-7
pubmed: 17251558